GMP Custom Peptide Development

We manufacture peptides up to 50 amino acids in length and in quantities that can range from a gram to multi-10kg quantities. Our robust, economical manufacturing processes help optimise the cost of development.

A full range of synthetic technologies are available. The final choice depends on the sequence length, the scale, and the specific project requirements.

Large-Scale Liquid (Solution) Phase Peptide Synthesis (LPPS)

LPPS is the technology of choice for manufacturing short peptides or structures that are inappropriate for a resin matrix. This approach ultimately provides a cost-effective process for large-scale manufacture of multi-10kg to multi-100kg lots.

Large-Scale Solid Phase Peptide Synthesis (SPPS)

SPPS is the technology of choice for manufacturing most peptides in up to multi-10kg quantities, especially those with longer, more complex sequences. We offer both Fmoc- and tBoc-based solid-phase manufacturing.

Large-Scale Hybrid Fragment Synthesis

This technology, which involves coupling shorter, SPPS generated sequences together in solution, is particularly suitable for some longer peptide structures, offering higher yields than “straight-through” SPPS.

Large-Scale Purification

Modern preparative high-pressure liquid chromatography (HPLC) technology has greatly facilitated the bulk manufacture of high purity peptides, suitable for pharmaceutical applications. Thanks to the available technology, the latest equipment and high level expertise, the PolyPeptide Group is capable of achieving the necessary purity of products at almost any scale, from a few grams or less to a 100kg or more.

Purification is usually performed by liquid-phase chromatography, using:

• Reverse-phase HPLC with columns up to 60 cm in diameter
• Ion exhange chromatography with columns up to 1 meter in diameter
• Size exclusion chromatography up to 1 meter in diameter

Large-Scale Isolation

Final isolation of peptides is typically achieved by lyophilisation, using:

• Bottle and tray lyophilisers permitting the isolation of single lots of up to 10kg for highly soluble peptides
• Tray lyophilisers of 200kg of ice capacity: these are the largest currently used in commercial synthetic peptide manufacture by any organisation

Alternative isolation procedures such as precipitation and spray drying, which can be scaled to process significantly larger single lots than lyophilisation permits, are being explored for appropriate APIs.